News
Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, ...
The Window of Opportunity: Why Early Biologic Use Matters for Patients With Hidradenitis Suppurativa
Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...
2d
Medpage Today on MSNGLP-1 Drugs May Hold Benefit in Painful Skin Disease
In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...
Hidradenitis suppurativa patients face higher depression and anxiety risks, but biologic treatments may reduce these mental ...
GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...
8h
TipRanks on MSNIncyte’s Promising Phase 3 Study on Ruxolitinib Cream for Hidradenitis Suppurativa
Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Study Overview: Incyte Corporation is conducting a Phase ...
8h
TipRanks on MSNIncyte’s Phase 3 Study on Ruxolitinib Cream: A Potential Breakthrough for Hidradenitis Suppurativa
Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a Phase 3 clinical study ...
The dermatology team at Zulekha Hospital is trained in the latest biological therapies ...
Explore how hidradenitis suppurativa is linked to increased rates of depression and anxiety, with no clear connection to ...
3h
Onlymyhealth on MSNHow Women Can Take Care Of Their Menopausal Skin: Expert Insights
Menopause often brings unexpected changes to your skin from dryness to sensitivity Here’s what a doctor advises to keep your ...
Avalo Therapeutics (NASDAQ:AVTX) stock rises as Cantor Fitzgerald launches coverage with an Overweight rating, highlighting its lead asset, AVTX-009. Read more here.
Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results